Vibrant Longevity Summit 2025 to Welcome Global Leaders Shaping the Future of Longevity Clinics

September 3, 2025 9:30 AM

The Vibrant Longevity Summit will welcome longevity clinic owners, pioneering physicians, and world-renowned experts for three days of science, strategy, and community. This second annual, by-application-only event is offered at no cost to approved attendees and will take place at the Omni Barton Creek Resort in Austin, Texas.A faculty of internationally recognized leaders-including Dr. Peter Attia, Dr. Andrew Huberman, Dr. Gabrielle Lyon, Dr....

Read more

PLPC-DB: De-Risked Oncology Immunotherapy Asset With Global Licensing Window and STIP-NAM Framework

September 3, 2025 8:00 AM

OGRD Alliance introduces PLPC-DB™, a next-generation, non-cellular oncology immunotherapy platform now entering a global acquisition window. Unlike cell- or gene-based products, PLPC-DB™ is a lyophilized phospholipoproteic complex stable for more than 18 months at room temperature, eliminating cold-chain dependency and reducing infrastructure costs by over 60%. The platform is anchored in the Structured Immunophenotypic Traceability Platform...

Read more

Alligator Announces Evaluation and Option Agreement Covering RUBY(TM) Antibody Format

September 2, 2025 10:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that Alligator has entered into an evaluation and option agreement with an infectious disease company regarding its proprietary RUBY™ bispecific antibody format.The evaluation and option agreement relates to the application of the RUBYTM platform in specific infectious diseases. The agreement includes a two-year evaluation period and provides the counterparty with an exclusive option...

Read more

NAYA Therapeutics to Partner With Atley Solutions to Accelerate Development & Commercialization of Its Astatine-211 Radio Pharmaceuticals

September 2, 2025 9:15 AM

NAYA Therapeutics ("NAYA"), a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of astatine-211 (²¹¹At) targeted alpha therapies (TATs) and NK cell engaging bifunctional antibodies today announced that it has selected Atley Solutions, global leader in commercial products and services for astatine-related pharmaceutical development and manufacturing, as a partner and...

Read more

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

September 2, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in Alzheimer's dementia, to a new international site at Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Canada. "Bringing CALMA to Canada is a milestone in our mission to offer innovative solutions for individuals living with Alzheimer's disease," said...

Read more

AlivaMab Biologics Announces Milestone- and Royalty-Free Access to AlivaMab(R) Mouse for Human Antibody Drug Discovery Services

September 2, 2025 8:00 AM

AlivaMab Biologics, LLC ("AMB"), a leader in the discovery and engineering of superior biologic drugs, today announced that the AlivaMab Mouse platform, a suite of transgenic mice for fully human antibody drug discovery, is now available on a license-, milestone- and royalty-free basis for partners engaging AMB for antibody drug discovery and engineering services."We are thrilled to offer the newest generations of AlivaMab Mouse, the most...

Read more

Ablexis Announces Validation and Availability of AlivaMab(R) Mouse-NGX

September 2, 2025 8:00 AM

Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab Mouse technology, today announced the launch of AlivaMab Mouse-NGX, a next-generation suite of advanced transgenic mice that expand both the number and human variable region diversity of antigen-specific antibodies while retaining their requisite drug-like properties."AlivaMab Mouse-NGX strains represent a major...

Read more

BioInvent Announces Board of Directors Update

September 2, 2025 4:30 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that Vincent Ossipow has stepped down from the Company's Board of Directors, effective today. The Board wishes to express its gratitude for Vincent's valuable contributions and dedication throughout his tenure.Vincent Ossipow...

Read more

Immortal Dragons Backs Frontier Bio: Advancing 3D Biofabrication for Tissue Engineering

August 29, 2025 8:45 AM

Immortal Dragons, the $40 million purpose-driven longevity fund, today announced its strategic investment in Frontier Bio, a biotechnology company at the forefront of biofabrication, drawing on a suite of technologies including 3D biofabrication, stem cells, organ-on-a-chip, and perfusion bioreactor technology. Their blood vessel technology addresses critical unmet medical needs in markets worth over $12 billion annually where current synthetic...

Read more

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

August 28, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application US 17/613,909. The patent application, IGC510, is for a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette's syndrome with THC and/or CBD. A notice of allowance ("NOA") for a patent application means that claims have been...

Read more

Vicore to Present at Upcoming Investor Conferences

August 28, 2025 2:20 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following conferences:Cantor Global Healthcare Conference 2025Location: New York, USAFormat: Fireside chat and 1x1 meetingsPresentation Date and Time: Wednesday, September 3 at 1:00 PM ET Webcast: RegistrationParticipants: Ahmed Mousa, CEO Wells Fargo Healthcare Conference...

Read more

FluoGuide A/S Publishes Interim Report H1 2025

August 28, 2025 1:50 AM

FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 28 August 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 30 June 2025. The H1 report is available as an attached document to this press release and on FluoGuide's website.Operational Highlights - H1 2025· FluoGuide receives approval for phase II trial of FG001 for head and neck cancer (CT-005)· FluoGuide enrolls first patient in CT-005·...

Read more

Exercise Price Determined for the Exercise of Warrants Series TO 13 in Alligator Bioscience AB

August 27, 2025 3:15 PM

Alligator Bioscience AB (STO:ATORX) ("Alligator Bioscience" or the "Company") hereby announces that the exercise price for warrants series TO 13 (the "warrants") has been determined to SEK 3.12. The exercise period for the warrants commences on 1 September 2025 and runs up to and including 15 September 2025. The last day of trading in the warrants is 11 September 2025.Alligator Bioscience carried out a rights issue of units during December 2024...

Read more

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

August 27, 2025 9:45 AM

Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered biodefense, drug discovery and advanced diagnostics. The new name underscores the Company's commitment to harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities.Building...

Read more

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."

August 27, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or...

Read more

Faron Pharmaceuticals Ltd: Half-Year Financial Results 1 January - 30 June 2025

August 27, 2025 2:20 AM

Faron Pharmaceuticals Ltd (AIM: FARN, First North:FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, has published its unaudited half-year financial results for the six months ended 30 June 2025, on 27 August 2025.Figures in parentheses refer to the corresponding period of previous year, unless otherwise...

Read more

BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical Programs and Enhance Value Creation

August 26, 2025 2:50 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced a strategic portfolio optimization initiative to maximize the probability of success for its lead clinical programs and optimize resource allocation across its portfolio, with an intensified focus on our most promising...

Read more

BioInvent International AB: Interim Report January - June 2025

August 26, 2025 2:50 AM

BioInvent International (STO:BINV) - "This is an important next step for BioInvent," said Martin Welschof, Chief Executive Officer of BioInvent. "We are sharpening our clinical focus on our most advanced assets with the greatest potential impact and multiple upcoming catalysts, thus maintaining a strong foundation for future growth. Our decision reflects a disciplined, opportunity-driven approach that we believe will maximize both patient impact...

Read more

Lifeloc Unveils SpinDetect(TM) Centrifugal Drug Analyzer at First Customer Demonstrations

August 25, 2025 4:12 PM

Lifeloc Technologies, Inc. (OTCID:LCTC), a U.S. leader in portable alcohol and drug testing solutions, unveiled its new SpinDetect™ Centrifugal Drug Analyzer during live demonstrations at the International Association of Chiefs of Police Impaired Driving and Traffic Safety Conference held in Chicago, August 4-6, 2025. The SpinDetect™ system brings lab-grade analytical chemistry onto a compact, automated disk platform that can be run with...

Read more

Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy

August 25, 2025 10:00 AM

Vexing challenges await cancer researchers every day -- not just in finding new molecules -- but now, increasingly, in finding new ways to make tumors more vulnerable to existing drugs.Tumors have their own defense mechanisms, designed to thwart therapeutic intruders, and the immune system is often unable to mount an effective response.Dozens of companies are working in this area but Actuate Therapeutics (NASDAQ:ACTU) reports it has made more...

Read more